

# **RAF Proto Oncogene Serine, Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update**

<https://marketpublishers.com/r/R4B5A49CE687EN.html>

Date: November 2022

Pages: 117

Price: US\$ 3,500.00 (Single User License)

ID: R4B5A49CE687EN

## **Abstracts**

RAF Proto Oncogene Serine, Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

### **SUMMARY**

RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - RAF proto-oncogene serine/threonine-protein kinase or proto-oncogene c-RAF is an enzyme is encoded by the RAF1 gene. Once activated the cellular RAF1 protein can phosphorylate to activate the dual specificity protein kinases MEK1 and MEK2 which in turn phosphorylate to activate the serine/threonine specific protein kinases, ERK1 and ERK2. It plays an important role in the control of gene expression involved in the cell division cycle, apoptosis, cell differentiation and cell migration.

RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) pipeline Target constitutes close to 22 molecules. Out of which approximately 16 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 6, 3, 5 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 4 and 2 molecules, respectively. Report covers products from therapy areas Oncology and Genetic

Disorders which include indications Solid Tumor, Colorectal Cancer, Melanoma, Non-Small Cell Lung Cancer, Breast Cancer, Gastric Cancer, Esophageal Cancer, Gastrointestinal Stromal Tumor (GIST), Hepatocellular Carcinoma, Liver Cancer, Lung Cancer, Metastatic Colorectal Cancer, Metastatic Melanoma, Unspecified Cancer, Adenocarcinoma Of The Gastroesophageal Junction, Adenoid Cystic Carcinoma (ACC), Anaplastic Astrocytoma, Bile Duct Cancer (Cholangiocarcinoma), Bladder Cancer, Blood Cancer, Cervical Cancer, Chondrosarcoma, Chordoma, Craniopharyngioma, Endometrial Cancer, Esophageal Squamous Cell Carcinoma (ESCC), Ewing Sarcoma, Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastroesophageal (GE) Junction Carcinomas, Glioblastoma Multiforme (GBM), Glioma, Head And Neck Cancer Squamous Cell Carcinoma, Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2<sup>+</sup> Breast Cancer), Kidney Cancer (Renal Cell Cancer), Letterer-Siwe Disease (Multifocal and multisystemic (disseminated) Langerhans-cell histiocytosis), Liposarcoma, Low-Grade Glioma, Malignant Glioma, Medullary Thyroid Cancer, Metastatic Adenocarcinoma of The Pancreas, Metastatic Biliary Tract Cancer, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Pancreatic Cancer, Metastatic Uveal Melanoma, Multiple Myeloma (Kahler Disease), Myelodysplastic Syndrome, Myelofibrosis, Non-Small Cell Lung Carcinoma, Oropharyngeal Cancer, Osteosarcoma, Ovarian Cancer, Pancreatic Ductal Adenocarcinoma, Peritoneal Cancer, Prostate Cancer, Rectal Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Renal Cell Carcinoma, Rhabdomyosarcoma, Sarcomas, Soft Tissue Sarcoma, Transitional Cell Cancer (Urothelial Cell Cancer) and Triple-Negative Breast Cancer (TNBC).

The latest report, outlays comprehensive information on the RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1)

The report reviews RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects

The report assesses RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics

## REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Overview

RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Companies Involved in Therapeutics Development

Apollomics Inc

Bayer AG

Chengdu Fanxi Biopharma Co Ltd

Deciphera Pharmaceuticals Inc

Hanmi Pharmaceuticals Co Ltd

Jazz Pharmaceuticals Plc

Metagone Biotech Inc

Novartis AG

Quanta Therapeutics Inc

Samjin Pharm Co Ltd

Sirnaomics Ltd

SyntheX Inc

Takeda Pharmaceutical Co Ltd

Verastem Inc

RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Drug Profiles

(MG-005 + sorafenib) - Drug Profile

Product Description

Mechanism Of Action

History of Events  
(MG-010 + sorafenib) - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
APL-102 - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
avutometinib - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
belvarafenib - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
DCBCI-0902 - Drug Profile  
Product Description  
Mechanism Of Action  
DCC-3084 - Drug Profile  
Product Description  
Mechanism Of Action  
FNX-006 - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
FYA-1001 - Drug Profile  
Product Description  
Mechanism Of Action  
JZP-815 - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
naporafenibum - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
regorafenib - Drug Profile

Product Description

Mechanism Of Action

History of Events

SJP-1601 - Drug Profile

Product Description

Mechanism Of Action

History of Events

SJP-601 - Drug Profile

Product Description

Mechanism Of Action

Small Molecule to Inhibit FLT, FLT3, FLT4, FMS, c-KIT, LYN, RAF1, RET, PDGFRa and PDGFRb for Oncology - Drug Profile

Product Description

Mechanism Of Action

Small Molecule to Inhibit Pan-RAF Kinase for Oncology - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Inhibit CRAF and BRAF for Oncology - Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Inhibit RAF for Unspecified Cancer - Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Inhibit RAF1 for Unspecified Cancer - Drug Profile

Product Description

Mechanism Of Action

STP-902 - Drug Profile

Product Description

Mechanism Of Action

STX-200 - Drug Profile

Product Description

Mechanism Of Action

tovorafenib - Drug Profile

Product Description

Mechanism Of Action

History of Events

RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Dormant Products

RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Discontinued Products

RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Product Development Milestones

Featured News & Press Releases

Nov 11, 2022: Day One announces upcoming presentations at 2022 Society for Neuro-Oncology Annual Meeting

Oct 04, 2022: Verastem Oncology announces RAMP VS-6766 clinical trials and corporate updates

Sep 21, 2022: Global Coalition for Adaptive Research announces that Regorafenib has completed follow-up in the Gbm Agile trial for patients with glioblastoma

Jun 15, 2022: FDA grants IND clearance for Jazz and Redx's cancer drug application

Jun 12, 2022: Day One announces positive initial data from pivotal FIREFLY-1 trial of tovorafenib (DAY101) in relapsed pediatric low-grade glioma

Jun 06, 2022: Verastem Oncology provides update on RAMP 201 study evaluating VS-6766 defactinib in low-grade serous ovarian cancer

May 23, 2022: Day One announces first patients dosed in phase 1b/2 combination study with tovorafenib (DAY101) and pimasertib in RAF-altered solid tumors

May 18, 2022: Verastem Oncology awarded Pancreatic Cancer Action Network's first therapeutic Accelerator Award to evaluate the combination of VS-6766 and Defactinib in front-line metastatic pancreatic cancer

Apr 08, 2022: Jazz Pharmaceuticals presents pre-clinical data for pan-RAF inhibitor JZP815, including pharmacokinetic properties and efficacy in multiple solid tumor types

Mar 28, 2022: Verastem Oncology provides financial update to support development of VS-6766 and defactinib in RAS pathway-driven tumors

Mar 08, 2022: Jazz Pharmaceuticals to present Pan-RAF inhibitor pre-clinical data at American Association for Cancer Research (AACR) 2022 Annual Meeting

Nov 22, 2021: Day One announces first patient dosed in phase 2 monotherapy study in RAF-altered solid tumors

Nov 03, 2021: Day One announces presentation at 2021 Connective Tissue Oncology Society (CTOS) Virtual Annual Meeting

Sep 19, 2021: ICR says drug combo demonstrates effectiveness in ovarian cancer trial

Sep 09, 2021: Bayer to present abstracts on Stivarga (regorafenib) at ESMO Congress 2021

Appendix

Methodology

Coverage

Secondary Research

Primary Research



[Expert Panel Validation](#)

[Contact Us](#)

[Disclaimer](#)

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indications, 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Number of Products under Investigation by Universities/Institutes, 2022

Products under Investigation by Universities/Institutes, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Pipeline by Apollomics Inc, 2022

Pipeline by Bayer AG, 2022

Pipeline by Chengdu Fanxi Biopharma Co Ltd, 2022

Pipeline by Deciphera Pharmaceuticals Inc, 2022

Pipeline by Hanmi Pharmaceuticals Co Ltd, 2022

Pipeline by Jazz Pharmaceuticals Plc, 2022

Pipeline by Metagone Biotech Inc, 2022

Pipeline by Novartis AG, 2022

Pipeline by Quanta Therapeutics Inc, 2022

Pipeline by Samjin Pharm Co Ltd, 2022

Pipeline by Sirnaomics Ltd, 2022

Pipeline by SyntheX Inc, 2022

Pipeline by Takeda Pharmaceutical Co Ltd, 2022

Pipeline by Verastem Inc, 2022

Dormant Products, 2022

Dormant Products, 2022 (Contd..1)

Dormant Products, 2022 (Contd..2)

Discontinued Products, 2022

## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

## I would like to order

Product name: RAF Proto Oncogene Serine, Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/R4B5A49CE687EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/R4B5A49CE687EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970